Sino Biopharmaceutical has announced two significant international agreements that strengthen its position in respiratory medicine, expanding collaborations with both AstraZeneca and GSK as global pharmaceutical partnerships continue to accelerate.

The Wall Street Journal highlighted that the company has entered a licensing agreement with AstraZeneca for its investigational chronic respiratory treatment TQC3721 while also expanding its commercial partnership with GSK in mainland China.

Under the AstraZeneca agreement, subsidiary Chia Tai Tianqing Pharmaceutical has granted the company exclusive rights to develop, manufacture and commercialise TQC3721 outside China. The investigational therapy is a phosphodiesterase (PDE3/4) inhibitor designed for chronic respiratory diseases.

The agreement includes an upfront payment of US$200 million, with the potential value reaching up to US$1.9 billion through development, regulatory and commercial milestone payments. Sino Biopharmaceutical is also eligible to receive tiered royalties linked to future global sales.

The partnership represents the company's second international out-licensing agreement with a multinational pharmaceutical business this year, following an earlier agreement with Sanofi announced in February.

Alongside the AstraZeneca collaboration, Sino Biopharmaceutical has also strengthened its relationship with GSK by securing commercialisation rights for two respiratory therapies, Trelegy Ellipta and Anoro Ellipta, in mainland China.

The company will oversee the importation, distribution, hospital access and promotional activities for both medicines, expanding its respiratory portfolio while supporting wider patient access within the Chinese market.

The agreements reflect the growing momentum behind strategic collaborations between multinational pharmaceutical companies and Chinese biopharmaceutical organisations. Licensing partnerships are increasingly being used to accelerate innovation, broaden market access and combine research capabilities with commercial expertise across global healthcare markets.

As pharmaceutical companies continue seeking opportunities to strengthen respiratory treatment portfolios, cross-border licensing and commercial partnerships remain an important strategy for expanding innovation while supporting long-term growth across international markets.